Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction

Full Text


  1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 1994; 308: 81-106.
  2. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br. Med. J. 2002; 324: 71-86.
  3. ISIS-2 (second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332: 349- 360.
  4. The Clopidogrel in Unstable Angina to prevent Reccurrent Events Trial Investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.
  5. Metha S., Yusuf S., Peters R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE Study. Lancet 2001; 358: 527-533.
  6. Steinhubl S., Berger P., Mann J. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. J. A. M. A. 2002; 288: 2411-2420.
  7. Sabatine M., Cannon C., Gibson C. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 2005; 352 (12): 1179-1189.
  8. Chen Z., Jiang L., Chen Y. et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497): 1607-1621.
  9. Topol E. J., Gum P., Kottle-Marchant K. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: reply. J. Am. Coll. Cardiol. 2003; 42: 1336-1337.
  10. Serebruany V. L. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 2005; 45: 51.
  11. Gum P. A., Kottke-Marchant K., Welsh P. A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 2003; 41: 961-965.
  12. Chen W.-H., Lee P. Y., Nig W. et al. Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J. Am. Coll. Cardiol. 2005; 45: 382A.
  13. Sane D. C., McKee S. A., Malinin A. I., Serebruany V. L. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am. J. Cardiol. 2002; 90: 893-895.
  14. Gurbel P. A., Blinden K. P. Interpretation of platelet inhibition by clopidogrel and the effect on non-responders. J. Thromb. Haemost. 2003; 1: 1318-1319.
  15. Lepantalo A., Virtanen K. S., Heikkil J. et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur. Heart. J. 2004; 25: 476-483.
  16. Gum P. A., Kottke-Marchant K., Poggio E. D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001; 88: 230-235.
  17. Altman R., Luciardi H. L., Muntaner J., Herrera R. N. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb. J. 2004; 2 (1): 1-8.
  18. Friend M., Vucenik I., Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. Br. Med. J. 2003; 326: 82-83.
  19. Macchi L., Christiaens L., Brabant S. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 2002; 107: 45-49.
  20. Muller I., Besta F., Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 2003; 89: 783-789.
  21. Golanski J., Chopicki S., Golanski R. et al. Resistance to aspirin after coronary arterybypass grafting is transient: impact the monitoring of aspirin antiplatelet therapy. Ther. Drug Monit. 2005; 27: 484-490.
  22. Syrbe G., Redlich H., Weidlich B. et al. Individual dosing of ASA prophylaxis by controlling platelet aggregation. Clin. Appl. Thromb. Hemost. 2001; 7: 209-213.
  23. Erlinge D., Borna C., Lazarowski E. et al. Resistance to aspirin in increased by ST-elevation myocardial infarction and correlates wuth adenosine diphosphate levels. Thromb. J. 2005; 3: 10.
  24. Wang Т. Н., Bhatt D. L., Topol E. J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart. J. 2006; 27: 647-654.
  25. Gotter G., Shemesh E., Zehavi M. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am. Heart J. 2004; 147: 293-300.
  26. Merlini P. A., Bauer K. A., Oltrona L. et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.
  27. Angiolillo D. J., Fernandez -Ortiz A., Bernardo E. et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J. Cardiol. 2006; 97 (1): 38-43.
  28. Mehta S. S., Silver R. J., Aaronson A. et al. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am. J. Cardiol. 2006; 97 (4): 567-570.
  29. Morrow J. D., Frei В., Longmire A. W. et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 1995; 332: 1198-1203.
  30. Davi G., Giabattoni G., Consoli A. et al. In vivo formation of 8-iso-prostaglandin F2-alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
  31. Pulcinelli F. M., Pignatelli P., Celestini A. et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term-treated patients. J. Am. Coll. Cardiol. 2004; 43: 979-984.
  32. Steinhubl S. R. Antiplatelet therapy: aspirin. J. Invas. Cardiol. 2003; 15: 1311-1316.
  33. Catella-Lawson F., Reilly M. P., Kapoor S. C. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 2001; 345: 1809-1817.
  34. MacDonald T. M., Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.
  35. Lau W. C., Waskell L. A., Watkins P. B. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
  36. Saw J., Steinhubl S. R., Berger P. B. et al. Lack of adverse clopidogrel - atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
  37. Smith S. M., Judge H. M., Peters G., Storey R. F. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004; 15 (8): 465-474.
  38. Vinholt P., Poulsen T. S., Korholm L. et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb. Haemost. 2005; 94 (2): 438-443.
  39. Serebruany V. L., Malinin A. S., Callahan K. P. et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001; 159: 239-241.
  40. Serebruany V. L., Midei M. G., Malinin A. I. et al. Absence of interaction between atorwastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. 2004; 164 (l8): 2051-2057.
  41. Tafreshi M. J., Zagnoni L. G., Gentry E. J. Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma? Pharmacotherapy 2006; 26 (3): 388-394.
  42. Weber A. A., Zimmerman K. C., Mayer-Kirchrath J. et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
  43. Karim S., Habib A., Levy-Toledano S. et al. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J. Biol. Chem. 1996; 271 (20): 1242-1248.
  44. Valles J., Santos M. T., Aznar J. et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350-355.
  45. Fontana P., Dupont A., Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene seguence variations in healthy subjects. Circulation 2003; 108: 989-995.
  46. Undas A., Brummel K., Musial J. et al. PI(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-2672.
  47. Pontiggia L., Lassila R., Pederiva S. et al. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphism of platelet GPIa and GPIIIa. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 2093-2098.
  48. Hankei G. J., Eikelboom J. W. Aspirin resistance. Lancet 2006; 1 (8) 606-617.
  49. Eikelboom J. W., Hirsh J., Weitz J. I. et al. Aspirinoresistant thromboxane biosynthesis and the risk of myocardial thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
  50. Bhatt D. L., Topol E. J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. 2003; 2: 15-28.
  51. Matetzky S., Shenkman В., Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
  52. Cuisset Т., Frere C., Quilici J. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 2006; 4: 512-549.
  53. de Gaetano G., Donati M. B., Cerletti C. Prevention on thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol. Sci. 2003; 24: 245-252.
  54. Peters R. J. G., Metha S. R., Fox K. A. A. et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prenent Recurrent Events (CURE) Study. Circulation 2003; 108: 1682-1687.
  55. Topol E. J., Easton D., Harrington A. et al. Randomized, double-blind, placebo-controlled, international trial of the oral Ilb/IIIa antagonist lotrofiban in coronary and cerebrovascular disease. Circulation 2003; 108: 399-406.
  56. Angiolillo S., Bernardo F., Ramirez A. et al. Effects of a high clopidogrel loading dose on platelet response and interindividual variability during coronary stenting. Eur. Heart. J. 2004; 25 (suppl.): Abstr. 559.
  57. von Beckerath N., Taubert D., Pogatsa-Murray G. et al. Absorption, metabolization, and antiplatelet effects of 300, -600, -and 900 mg loading doses of clopidigrel: results of the ISAR-CHOICE Trial. Circulation 2005; 112: 2946-2950.
  58. Patti G., Colonna G., Pasceri V. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 Study. Circulation 2005; 111: 2099-2106.
  59. Asfour A. I., Greenbaum A. B., McFarland A. et al. Facilitated angioplasty with combined ADP P2T receptor blockade and fibrinolysis for the treatment of acute myocardial infarction: results from the STEP-AMI trial. J. Am. Coll. Cardiol. 2002; 39: 39.
  60. Greenbaum A. B., Ohman E. M., Gibson M. S. et al. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction. J. Am. Coll. Cardiol. 2002; 39: 281.



Abstract: 152

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2008 Kremneva L.V., Shalaev S.V., Kremneva L.V., Shalaev S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies